Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease

Journal of Clinical Gastroenterology

Volumn 41, Issue 7, 2007, Pages 682-688

  Ananthakrishnan, Ashwin N ^a   Attila, Tan ^a   Otterson, Mary F ^a   Lipchik, Randolph J ^a   Massey, Benson T ^a   Komorowski, Richard A ^a   Binion, David G ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

6 mercaptopurine; Adverse drug reaction; Azathioprine; BOOP; Bronchiolitis obliterans; Crohn's disease; Inflammatory bowel disease; Organizing pneumonia; Pulmonary toxicity; Purine analog; Ulcerative colitis

Indexed keywords

ACICLOVIR; ALPRAZOLAM; AZATHIOPRINE; AZITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; INFLIXIMAB; LANSOPRAZOLE; MERCAPTOPURINE; MESALAZINE; PREDNISONE; TAMSULOSIN;

ADULT; AGED; ARTICLE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; BRONCHOSCOPY; CASE REPORT; COUGHING; DISEASE COURSE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSPNEA; ENTERITIS; FEMALE; FEVER; FLU LIKE SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; MALE; OPEN LUNG BIOPSY; PRIORITY JOURNAL; PULMONARY TOXICITY; RETROSPECTIVE STUDY;

6-MERCAPTOPURINE; ADULT; AGED; AZATHIOPRINE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; MALE; SEVERITY OF ILLNESS INDEX;

EID: 34547653880     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000225577.81008.ee     Document Type: Article

References (35)

1. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000;2:CD000067.
2. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
3. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000;2:CD000545.
4. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl. 1998;225:92-99.
5. Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol. 2005;100:1121-1125.
6. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology. 2004;127:730-740.
7. Singleton JW, Law DH, Kelley ML, Jr, et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology. 1979;77:870-882.
8. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423-433.
9. Saway PA, Heck LW, Bonner JR, et al. Azathioprine hypersensitivity. Case report and review of the literature. Am J Med. 1988;84:960-964.
10. Rubin G, Baume P, Vandenberg R. Azathioprin nd acute restrictive lung disese. Aust N Z J Med. 1972;2:272-274.
11. Nagy F, Molnar T, Makula E, et al. Azathioprine-associated interstitial pneumonitis. Orv Hetil. 2006;147:259-262.
12. Bedrossian CW, Sussman J, Conklin RH, et al. Azathioprine-associated interstitial pneumonitis. Am J Clin Pathol. 1984;82:148-154.
13. Brown AL, Corris PA, Ashcroft T, et al. Azathioprine-related interstitial pneumonitis in a renal transplant recipient. Nephrol Dial Transplant. 1992;7:362-364.
14. Fauroux B, Meyer-Milsztain A, Boccon-Gibod L, et al. Cytotoxic drug-induced pulmonary disease in infants and children. Pediatr Pulmonol. 1994;18:347-355.
15. Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore). 1993;72:151-183.
16. Mahajan L, Kay M, Wyllie R, et al. Ulcerative colitis presenting with bronchiolitis obliterans organizing pneumonia in a pediatric patient. Am J Gastroenterol. 1997;92:2123-2124.
17. Yano S, Kobayashi K, Kato K, et al. A limited form of Wegener's granulomatosis with bronchiolitis obliterans organizing pneumonitis-like variant in an ulcerative colitis patient. Intern Med. 2002;41:1013-1015.
18. Ulubas B, Sahin G, Ozer C, et al. Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. Clin Rheumatol. 2004;23:249-251.
19. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:104-115.
20. Carmichael DJ, Hamilton DV, Evans DB, et al. Interstitial pneumonitis secondary to azathioprine in a renal transplant patient. Thorax. 1983;38:951-952.
21. Krowka MJ, Breuer RI, Kehoe TJ. Azathioprine-associated pulmonary dysfunction. Chest. 1983;83:696-698.
22. Perreaux F, Zenaty D, Capron F, et al. Azathioprine-induced lung toxicity and efficacy of cyclosporin A in a young girl with type 2 autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2000;31:190-192.
23. Stetter M, Schmidl M, Krapf R. Azathioprine hypersensitivity mimicking Goodpasture's syndrome. Am J Kidney Dis. 1994;23:874-877.
24. Weisenburger DD. Interstitial pneumonitis associated with azathioprine therapy. Am J Clin Pathol. 1978;69:181-185.
25. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.
26. Orth T, Peters M, Schlaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol. 2000;95:1201-1207.
27. Rhodes J, Bainton D, Beck P, et al. Controlled trial of azathioprine in Crohn's disease. Lancet. 1971;2:1273-1276.
28. Willoughby JM, Beckett J, Kumar PJ, et al. Controlled trial of azathioprine in Crohn's disease. Lancet. 1971;2:944-947.
29. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367:839-846.
30. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
31. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004;10:657-660.
32. Riegert-Johnson DL, Godfrey JA, Myers JL, et al. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis. 2002;8:186-191.
33. Panagi S, Palka W, Korelitz BI, et al. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease. Inflamm Bowel Dis. 2004;10:274-277.
34. Ostor AJ, Chilvers ER, Somerville MF, et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol. 2006;33:622-628.
35. Roelofs PM, Klinkhamer PJ, Gooszen HC. Hypersensitivity pneumonitis probably caused by cyclosporine. A case report. Respir Med. 1998;92:1368-1370.